SuperworthLantheus profit margin LNTH
Gross, operating and net profit as a share of revenue over the last twelve months, from 2014.
- Net margin, 12 months
- 17.7%
- Operating margin, 12 months
- 19.4%
- Net margin on a year earlier
- −0.1 pts
- Peer median
- 10.1%
Over the twelve months to Jun 30, 2026, Lantheus kept 17.7% of its revenue as net profit, with an operating margin of 19.4% and a gross margin of 60.1%.
Five years earlier its net margin was −7.3%.
The median for 10 diagnostics and research stocks of a similar size is 10.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 15.2% | 20.2% | 61.1% |
| FY2024 | 20.4% | 29.8% | 64.4% |
| FY2023 | 25.2% | 28.1% | 54.7% |
| FY2022 | 3.0% | 3.9% | 62.2% |
| FY2021 | −16.8% | −14.3% | 44.1% |
| FY2020 | −4.0% | −1.2% | 40.9% |
| FY2019 | 9.1% | 14.9% | 50.3% |
| FY2018 | 11.8% | 18.8% | 50.9% |
| FY2017 | 37.2% | 15.6% | 48.9% |
| FY2016 | 8.9% | 18.7% | 45.6% |
| FY2015 | −5.0% | 14.5% | 46.2% |
| FY2014 | −1.2% | 13.1% | 41.6% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 17.7% | −0.1 pts | 19.4% | |
| Q1 FY26 | 18.0% | +1.5 pts | 18.8% | |
| Q4 FY25 | 15.2% | −5.2 pts | 20.2% | |
| Q3 FY25 | 11.0% | −17.6 pts | 22.8% | |
| Q2 FY25 | 17.8% | −12.0 pts | 28.8% | |
| Q1 FY25 | 16.5% | −17.2 pts | 29.4% | |
| Q4 FY24 | 20.4% | −4.8 pts | 29.8% | |
| Q3 FY24 | 28.6% | +19.9 pts | 32.1% | |
| Q2 FY24 | 29.8% | +26.8 pts | 31.9% | |
| Q1 FY24 | 33.7% | +35.4 pts | 35.2% | |
| Q4 FY23 | 25.2% | +22.2 pts | 28.1% | |
| Q3 FY23 | 8.6% | −4.7 pts | 4.6% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Lantheus' size, closest first, today.
| Company | Profit margin |
|---|---|
| LNTHLantheus | 17.7% |
| BLLNBillionToOne | 9.5% |
| CAICaris Life Sciences | 10.6% |
| BIOBio-Rad Laboratories | 8.6% |
| VCYTVeracyte | 20.4% |
| CDNACareDx | 24.2% |
| RVTYRevvity | 8.2% |
| MEDPMedpace | 17.7% |
| LHLabcorp | 7.0% |
| DGXQuest Diagnostics | 9.2% |
| MTDMettler-Toledo International | 21.9% |
| Peer median | 10.1% |
Where Lantheus ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Lantheus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.